Company Carna Biosciences, Inc.

Equities

4572

JP3220550002

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 22:29:45 2024-05-26 EDT			5-day change	1st Jan Change
384 ^JPY	-1.03%		-9.86%	-26.44%

03-07	Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement	CI
2023	Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.

Number of employees: 67

JPY in Million	2022	Weight	2023	Weight	Delta
Drug Discovery Support 56.5 %	1,101	79.4 %	918	56.5 %	-16.58%
Drug Discovery 43.5 %	286	20.6 %	708	43.5 %	+147.39%

JPY in Million	2022	Weight	2023	Weight	Delta
North America 69.8 %	855	61.7 %	1,135	69.8 %	+32.67%
Japan 13.7 %	219	15.8 %	223	13.7 %	+2.08%
China 7.9 %	203	14.6 %	129	7.9 %	-36.57%
Europe 6.9 %	72	5.2 %	113	6.9 %	+56.84%
Other 1.6 %	38	2.7 %	26	1.6 %	-30.48%

Managers	Title	Age	Since
Kohichiro Yoshino PSD	President	75	03-04-09
Emi Yamamoto ADM	Chief Administrative Officer	53	03-12-31
Masaaki Sawa CTO	Chief Tech/Sci/R&D Officer	53	06-12-31
Akinori Arimura BRD	Director/Board Member	61	18-06-30
Norio Aikawa BRD	Director/Board Member	75	03-04-09

Members of the board	Title	Age	Since
Teruo Takayanagi BRD	Director/Board Member	77	15-02-28
Tsuguo Ogasawara BRD	Director/Board Member	84	05-02-28
Kohichiro Yoshino PSD	President	75	03-04-09
Norio Aikawa BRD	Director/Board Member	75	03-04-09
Atsuo Arita BRD	Director/Board Member	80	04-02-29
Takao Matsui BRD	Director/Board Member	68	19-02-28
Masaaki Sawa CTO	Chief Tech/Sci/R&D Officer	53	06-12-31
Emi Yamamoto ADM	Chief Administrative Officer	53	03-12-31
Akinori Arimura BRD	Director/Board Member	61	18-06-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	17,156,900	15,400,276 ( 89.76 %)	7,124 ( 0.0415 %)	89.76 %

Name	Equities	%	Valuation
ONO PHARMACEUTICAL CO., LTD. 2.941 %	504,500	2.941 %	1 M ¥
Toshihiko Uehara 2.144 %	367,800	2.144 %	1 M ¥
Kohichiro Yoshino 1.947 %	333,900	1.947 %	914 505 ¥
Kazuo Horita 1.768 %	303,300	1.768 %	830 696 ¥
Carna Biosciences Restricted Stock Compensation Plan 1.579 %	270,800	1.579 %	741 683 ¥
Takahiro Suzuki 1.399 %	240,000	1.399 %	657 326 ¥
Masaaki Sawa 0.6180 %	106,000	0.6180 %	290 319 ¥
Norio Aikawa 0.5947 %	102,000	0.5947 %	279 364 ¥
Emi Yamamoto 0.3183 %	54,600	0.3183 %	149 542 ¥
CARNA BIOSCIENCES, INC. 0.0414 %	7,100	0.0414 %	19 446 ¥

Name	Equities	%	Valuation
CARNA BIOSCIENCES, INC. 0.04%	7,100	0.04%	19,446 $

Carna Biosciences, Inc.

Kobe Biomedical Creation Center, 3/F 1-5-5 Minatojima-Minamimachi

650-0047, Kobe

http://www.carnabio.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CARNA BIOSCIENCES, INC.	-26.44%	42.4M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research